Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.03
  • Today's Change0.10 / 10.75%
  • Shares traded1.11m
  • 1 Year change-63.08%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in CNYView more

In 2023, cash reserves at Brii Biosciences Ltd fell by 700.92m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 594.01m for operations while cash used for investing totalled 104.35m.
Cash flow per share-0.3887
Price/Cash flow per share--
Book value per share4.31
Tangible book value per share3.91
More ▼

Balance sheet in CNYView more

Brii Biosciences Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio37.81
Quick ratio--
Total debt/total equity0.0069
Total debt/total capital0.007
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.